Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy
American Journal of Cardiovascular Drugs · 2025
DOI: 10.1007/s40256-025-00733-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cardiovascular Drugs, 2025. Verfasst von Yuansheng Wan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Ch…. Hauptthemen laut MEDLINE: Hypercholesterolemia, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Tafolecimab is a novel PCSK9 inhibitor developed in China. In recently published phase III clinical trials, tafolecimab demonstrated long-term safety and efficacy in Chinese patients with hypercholesterolemia despite statin therapy. However, pharmacoeconomic studies of tafolecimab have yet to be published. This study aimed to explore the maximum cost-effective price of tafolecimab compared with statins alone for Chinese patients with hypercholesterolemia at various willingness-to-pay (WTP) thresholds. METHODS: A Markov cohort state-transition model was employed to assess the cost-effectiveness of tafolecimab from the perspective of the Chinese healthcare system. The low-density lipoprotein cholesterol (LDL-C) lowering effect of tafolecimab was observed in the CREDIT-4 trial. The baseline and subsequent incidence and transfer probability of cardiovascular events were based on prospective observational data in China and meta-analyses from the Cholesterol Treatment Trialists Study. Cost and utility values were obtained from the China Health Statistics Yearbook, health insurance, and published articles in China. The study also performed subgroup, sensitivity, and scenario analyses. RESULTS: The annual price thresholds for tafolecimab as an adjunctive therapy to statins were Chinese yuan (CNY) 3304 and CNY 7022 at WTP thresholds of CNY 89,358 and CNY 268,074 per quality-adjusted life year (QALY), respectively. The corresponding annual price thresholds for patients with hypercholesterolemia with acute myocardial infarction were CNY 10,355 and CNY 21,793 per year. Sensitivity analyses showed that the time horizon significantly impacted price thresholds, with a several-fold difference. CONCLUSIONS: From the perspective of the Chinese healthcare system, the cost-effective annual price threshold for tafolecimab for patients with hypercholesterolemia was CNY 7022, at a threshold of CNY 268,074 per QALY.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China. youruxu2008@163.com.
Zitieren
APA
Wan, Y., Liu, J., Zhan, X., Zhang, Y., & You, R. (2025). Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-025-00733-0
Vancouver
Wan Y, Liu J, Zhan X, Zhang Y, You R. Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy. American Journal of Cardiovascular Drugs. 2025. doi:10.1007/s40256-025-00733-0
BibTeX
@article{Wan2025,
author = {Wan, Yuansheng and Liu, Jinyu and Zhan, Xiaolian and Zhang, Yu and You, Ruxu},
title = {Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy},
journal = {American Journal of Cardiovascular Drugs},
year = {2025},
doi = {10.1007/s40256-025-00733-0}
}
EUVIMED